Ask VialBase
sleep

DSIP

FDA: Research-only
Last updated · 2026-04-12

DSIP is a neuropeptide that modulates sleep-wake cycles by promoting delta wave activity during deep sleep stages. It also influences corticotropin release and stabilizes neuroendocrine regulation, supporting adrenal recovery and mitigating chronic stress. Targets thalamic and hypothalamic pathways involved in sleep regulation. Promotes delta wave activity during deep sleep stages. Influences corticotropin release and may stabilize neuroendocrine regulation, supporting adrenal recovery. Also enhances circadian rhythms and growth hormone processing, supports GABA tone, REM processing, and emotional resilience. - Deep sleep induction and improved sleep quality - Circadian rhythm reset and stabilization - Anxiety and stress reduction - Emotional grounding and

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight —
Half-life —
CAS number —
Route —
Where to buy DSIP →BioLongevity Labs · save 15% code VIALBASE
02

Research summary

Study Type Year Key Finding
Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Narrative mini-review (critical appraisal of the DSIP evidence base) 2006 States plainly that the link between DSIP and sleep 'has never been further characterized' since the 1977 Schoenenberger-Monnier isolation, in part because the DSIP gene, protein, and any related receptor were never isolated
Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Preclinical animal study (rabbit) — peptide isolation, synthesis, and double-blind EEG characterization 1977 Original 1977 isolation paper: a peptide that enhances slow-wave (delta) and spindle EEG activity after intraventricular (brain) infusion was isolated from rabbits and named delta-sleep-inducing peptide (DSIP)
Delta-sleep-inducing peptide reduces CRF-induced corticosterone release. Preclinical animal study in rats (intravenous dosing, neuroendocrine endpoints) — not a human study 1985 Rat study, not human: effects of the DSIP nonapeptide were tested on corticotropin releasing factor (CRF)-stimulated corticosterone release in rats treated with chlorpromazine-morphine-pentobarbital
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Double-blind, placebo-controlled crossover clinical trial in humans (short-term, four nights, 1987) with polysomnographic endpoints 1987 Small 1987 human crossover trial: DSIP 25 nmol/kg or placebo given intravenously over four nights in insomniac patients, with sleep assessed by polysomnography

Stacks containing DSIP

Anti-Anxiety Reset

Selank + BPC-157 + DSIP

Calm & Connection Sleep

DSIP + Oxytocin + Selank

Libido Lightning

PT-141 (Bremelanotide) + Oxytocin + DSIP

28-day resets featuring DSIP

03

Sourcing

Current prices

Updated today

2mg

Only vendor stocking this size on the VialBase roster.

5mg

10mg

Size unspecified

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code vialbase15 at checkout

Stocks this compound Third-party tested Public COAs Positive rep

Save 10% with code aewpzbzd at checkout

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • Cortisol (AM)
DURING CYCLE
  • Cortisol (AM)
POST-CYCLE
  • CMP
  • Cortisol (AM)
Safety & Regulatory Status
FDA STATUS Research-only. Not FDA-approved, not on the 503A bulks list, and not in any FDA interim category. An FDA advisory committee (PCAC) voted AGAINST recommending DSIP (Emideltide) for the 503A bulks list on 2026-07-24 — the only rejection of that meeting. Compounding DSIP is not permitted.

Regulatory status for DSIP may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is DSIP?
DSIP is a neuropeptide that modulates sleep-wake cycles by promoting delta wave activity during deep sleep stages.
How does DSIP work?
Targets thalamic and hypothalamic pathways involved in sleep regulation. Promotes delta wave activity during deep sleep stages.
How is DSIP dosed?
Standard: 100 mcg SubQ 30-60 minutes before bed (most common); Range: 100-500 mcg SubQ; Cycle: 4-6 weeks; can be used nightly for 3-5 days post-shift change; Route: SubQ injection; intranasal also noted. These figures reflect commonly cited research protocols, not medical advice — consult a clinician.
Is DSIP FDA-approved?
No. DSIP is a research-only compound, is not FDA-approved for human use, is not on the 503A bulks list, and does not appear in any of FDA's interim Category 1, 2, or 3 lists — so there is no lawful compounding route. On July 24, 2026 an FDA advisory committee (PCAC) voted **against** recommending DSIP (as Emideltide) for the 503A bulks list — the only rejection of a meeting at which the committee recommended six other peptides, and the only one where the committee agreed with FDA's own reviewers. The uses FDA evaluated were opioid withdrawal, chronic insomnia, and narcolepsy. DSIP is available only through research chemical suppliers and not in pharmaceutical-grade formulations in the US.

References

  1. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle.. Journal of neurochemistry (2006). PMID: 16539679
  2. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.. Proceedings of the National Academy of Sciences of the United States of America (1977). PMID: 265572
  3. Graf MV, Kastin AJ, Coy DH, et al.. Delta-sleep-inducing peptide reduces CRF-induced corticosterone release.. Neuroendocrinology (1985). PMID: 2995861
  4. Monti JM, Debellis J, Alterwain P, et al.. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.. International journal of clinical pharmacology research (1987). PMID: 3583493